title: Feasibility and impact of an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a tertiary care university medical center.
abstract: BACKGROUND
  Restricted use of third-generation cephalosporins and fluoroquinolones has been linked to a reduced incidence of hospital-acquired infections with multidrug-resistant bacteria. We implemented an intensified antibiotic stewardship (ABS) programme in the medical service of a university hospital center aiming at a reduction by at least 30% in the use of these two drug classes.
  
  
  METHODS
  The ABS programme was focused on the 300-bed medical service. Prescription of third-generation cephalosporins was discouraged, whereas the use of penicillins was encouraged. Monthly drug use density was measured in WHO-ATC defined and locally recommended daily doses (DDD and RDD) per 100 patient days, to evaluate trends before (01/2008 to 10/2011) and after starting the intervention (1/2012 to 3/2013). The effect was analysed using interrupted time-series analysis with six non-intervention departments as controls.
  
  
  RESULTS
  Following initiation of the ABS intervention, overall antibiotic use in the medical service declined (p < 0.001). There was a significant intervention-related decrease in the use of cephalosporins and fluoroquinolones (p < 0.001) outperforming the decreasing baseline trend. Trend changes observed in some of the control departments were smaller, and the difference between trend changes in the medical service and those in control departments were highly significant for overall use and cephalosporin use reductions (p < 0.001) as well as for the increasing use of penicillins (p < 0.001). Mean use density levels (in RDD per 100 patient days) dropped for cephalosporins from 16.3 to 10.3 (-37%) and for fluoroquinolones from 17.7 to 10.1 (-43%), respectively. During the same period, the use of penicillins increased (15.4 to 18.2; 18%). The changes in expenditures for antibiotics in the medical service compared to control services minus programme costs indicated initial net cost savings likely to be associated with the programme.
  
  
  CONCLUSIONS
  An intensified ABS programme targeting cephalosporin und fluoroquinolone use in the setting of a large academic hospital is feasible and effective. The intervention may serve as a model for other services and hospitals with a similar structure and baseline situation.
authors.affiliation: Department of Medicine, Abteilung Infektiologie, Universitätsklinikum Freiburg, Hugstetter Straße 55, D-79106 Freiburg i,Br, Germany. johannes.borde@web.de.
authors.forename: Johannes P
authors.initials: JP
authors.lastname: Borde
authors.forename: Klaus
authors.initials: K
authors.lastname: Kaier
authors.forename: Michaela
authors.initials: M
authors.lastname: Steib-Bauert
authors.forename: Werner
authors.initials: W
authors.lastname: Vach
authors.forename: Annette
authors.initials: A
authors.lastname: Geibel-Zehender
authors.forename: Hansjörg
authors.initials: H
authors.lastname: Busch
authors.forename: Hartmut
authors.initials: H
authors.lastname: Bertz
authors.forename: Martin
authors.initials: M
authors.lastname: Hug
authors.forename: Katja
authors.initials: K
authors.lastname: de With
authors.forename: Winfried V
authors.initials: WV
authors.lastname: Kern
mesh_terms: D000046:Academic Medical Centers / Q000458:organization & administration / Q000592:standards; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002511:Cephalosporins / Q000008:administration & dosage*; D003428:Cross Infection / Q000188:drug therapy / Q000517:prevention & control; D004363:Drug Utilization / Q000592:standards* / Q000706:statistics & numerical data; D017723:Drug Utilization Review / Q000458:organization & administration* / Q000592:standards; D024841:Fluoroquinolones / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D063128:Tertiary Health Care
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D024841:Fluoroquinolones
references.citation: Infect Control Hosp Epidemiol. 2000 Jan;21(1 Suppl):S12-7
references.pmid: 10654630
references.citation: J Antimicrob Chemother. 2012 Apr;67(4):1010-5
references.pmid: 22240401
references.citation: Infect Control Hosp Epidemiol. 2012 Apr;33(4):338-45
references.pmid: 22418628
references.citation: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003543
references.pmid: 16235326
references.citation: Emerg Infect Dis. 2006 Sep;12(9):1398-405
references.pmid: 17073089
references.citation: J Antimicrob Chemother. 2009 Mar;63(3):609-14
references.pmid: 19151036
references.citation: Rev Panam Salud Publica. 2011 Dec;30(6):603-9
references.pmid: 22358410
references.citation: J Antimicrob Chemother. 2012 Dec;67(12):2988-96
references.pmid: 22899806
references.citation: Infect Dis Clin North Am. 2011 Mar;25(1):245-60
references.pmid: 21316003
references.citation: Clin Infect Dis. 2005 Nov 1;41(9):1254-60
references.pmid: 16206099
references.citation: Int J Antimicrob Agents. 2013 Feb;41(2):137-42
references.pmid: 23276500
references.citation: Int J Antimicrob Agents. 2007 Jan;29(1):34-8
references.pmid: 17189092
references.citation: Br J Clin Pharmacol. 2012 Jul;74(1):171-9
references.pmid: 22150975
references.citation: J Antimicrob Chemother. 2008 Sep;62(3):593-600
references.pmid: 18467307
references.citation: J Antimicrob Chemother. 2013 Nov;68(11):2667-74
references.pmid: 23766490
references.citation: Value Health. 2012 Jan;15(1):87-93
references.pmid: 22264976
references.citation: Am J Med Sci. 1985 Dec;290(6):223-7
references.pmid: 3936358
references.citation: J Antimicrob Chemother. 2011 Sep;66(9):2168-74
references.pmid: 21676904
references.citation: Clin Infect Dis. 2007 Jan 15;44(2):159-77
references.pmid: 17173212
references.citation: J Antimicrob Chemother. 2010 Dec;65(12):2685-91
references.pmid: 20978000
references.citation: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003543
references.pmid: 23633313
references.citation: J Antimicrob Chemother. 2013 Dec;68(12):2934-9
references.pmid: 23873646
references.citation: Emerg Infect Dis. 2004 Aug;10(8):1432-41
references.pmid: 15496245
references.citation: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Nov;55(11-12):1418-26
references.pmid: 23114441
references.citation: Infect Control Hosp Epidemiol. 2009 Apr;30(4):346-53
references.pmid: 19236282